Investor relations
Dicot's drug candidate LIB-01, which aims at treating erection problems and premature ejaculation, is in the preclinical development phase.
The development is taking place under own auspice until phase 2 studies. Thereafter, the intention is to enter into strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies in order to be able to introduce LIB-01 to the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders.
IR contact

Elin Trampe
CEO
Email: elin.trampe@dicot.se
Tel: +46 73 980 14 08